Semaglutide and the Retina.
作者信息
Bloomgarden Zachary T
机构信息
Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
出版信息
J Diabetes. 2025 Apr;17(4):e70085. doi: 10.1111/1753-0407.70085.
Abstract
摘要
相似文献
1
Semaglutide and the Retina.司美格鲁肽与视网膜
J Diabetes. 2025 Apr;17(4):e70085. doi: 10.1111/1753-0407.70085.
2
Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?司美格鲁肽用于2型糖尿病——它是最佳的胰高血糖素样肽1受体激动剂（GLP-1R激动剂）吗？
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):371-377. doi: 10.1080/17425255.2018.1441286. Epub 2018 Feb 23.
3
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).在 2 型糖尿病患者中比较每周一次胰高血糖素样肽-1 受体激动剂（OW GLP-1RAs）与二肽基肽酶-4 抑制剂（DPP-4is）的降糖和减重效果的真实世界疗效（RELATE）。
Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20.
4
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?胰高血糖素样肽 1 受体激动剂与 A1c：对心脏有益，对眼睛却未必？
Diabetes Metab Syndr. 2023 Jan;17(1):102696. doi: 10.1016/j.dsx.2022.102696. Epub 2022 Dec 28.
5
Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.胰高血糖素样肽-1（GLP-1）激动剂起始使用的挑战：司美格鲁肽给药过量的案例系列。
Clin Toxicol (Phila). 2024 Feb;62(2):131-133. doi: 10.1080/15563650.2024.2322049. Epub 2024 Mar 12.
6
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病中的微血管作用：一项随机对照试验的荟萃分析。
Acta Diabetol. 2017 Oct;54(10):933-941. doi: 10.1007/s00592-017-1031-9. Epub 2017 Jul 27.
7
Glucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy.胰高血糖素样肽-1受体激动剂在糖尿病视网膜病变管理中的应用
Int Ophthalmol Clin. 2025 Jan 1;65(1):23-26. doi: 10.1097/IIO.0000000000000541. Epub 2024 Dec 23.
8
Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.口服司美格鲁肽，2 型糖尿病管理的新选择：叙述性综述。
Adv Ther. 2020 Oct;37(10):4165-4174. doi: 10.1007/s12325-020-01478-9. Epub 2020 Sep 4.
9
Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.接受胰高血糖素样肽-1受体激动剂治疗的2型糖尿病患者的心脏-肾脏比较结局：一项网状荟萃分析
Front Pharmacol. 2021 Dec 24;12:759262. doi: 10.3389/fphar.2021.759262. eCollection 2021.
10
Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.在现实环境中从使用胰高血糖素样肽-1受体激动剂转换为每周一次司美格鲁肽的2型糖尿病成年患者：SURE项目事后分析
Adv Ther. 2025 Feb;42(2):788-800. doi: 10.1007/s12325-024-03000-x. Epub 2024 Dec 5.
本文引用的文献
1
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.司美格鲁肽与糖尿病患者非动脉炎性前部缺血性视神经病变风险
JAMA Ophthalmol. 2025 May 1;143(5):400-407. doi: 10.1001/jamaophthalmol.2025.0349.
2
Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.司美格鲁肽的使用与非动脉炎性前部缺血性视神经病变风险：一项丹麦-挪威队列研究。
Diabetes Obes Metab. 2025 Jun;27(6):3094-3103. doi: 10.1111/dom.16316. Epub 2025 Mar 17.
3
Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide.与抗糖尿病药物司美格鲁肽和替尔泊肽相关的眼科并发症。
JAMA Ophthalmol. 2025 Mar 1;143(3):215-220. doi: 10.1001/jamaophthalmol.2024.6058.
4
Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes.在丹麦一个由424152名2型糖尿病患者组成的队列中，每周一次的司美格鲁肽使非动脉炎性前部缺血性视神经病变的五年风险增加了一倍。
Int J Retina Vitreous. 2024 Dec 18;10(1):97. doi: 10.1186/s40942-024-00620-x.
5
Influence of Common Medications on Diabetic Macular Edema in Type 2 Diabetes Mellitus.常用药物对2型糖尿病患者糖尿病性黄斑水肿的影响
Ophthalmol Retina. 2025 Jun;9(6):505-514. doi: 10.1016/j.oret.2024.12.006. Epub 2024 Dec 5.
6
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database.使用胰高血糖素样肽1受体激动剂的患者发生眼部药物不良反应的风险：一项基于美国食品药品监督管理局不良事件报告系统数据库的药物警戒研究
Endocrine. 2025 Apr;88(1):80-90. doi: 10.1007/s12020-024-04112-8. Epub 2024 Nov 22.
7
Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.司美格鲁肽与非动脉炎性前部缺血性视神经病变之间的关联：一项基于多国人群的研究。
Ophthalmology. 2025 Apr;132(4):381-388. doi: 10.1016/j.ophtha.2024.10.030. Epub 2024 Nov 2.
8
Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA.美国 2 型糖尿病合并动脉粥样硬化性心血管疾病患者 GLP-1RA 和 SGLT2i 的使用趋势。
BMJ Open Diabetes Res Care. 2024 Oct 4;12(5):e004431. doi: 10.1136/bmjdrc-2024-004431.
9
Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: A meta-analysis of clinical studies emphasising retinal changes as a primary outcome.胰高血糖素样肽-1受体激动剂对糖尿病视网膜病变的影响：一项以视网膜变化为主要结局的临床研究的荟萃分析
Clin Exp Ophthalmol. 2025 Jan-Feb;53(1):67-75. doi: 10.1111/ceo.14445. Epub 2024 Sep 26.
10
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.新型药物在糖尿病及其相关视网膜病变治疗中的应用。
Retina. 2024 Nov 1;44(11):1851-1859. doi: 10.1097/IAE.0000000000004252.
Zotero 插件